查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球基因工程工具市场——行业规模、份额、趋势、机会、2018-2028 年预测、按类型、按治疗领域、按最终用户、按地区、按竞争
市场调查报告书
商品编码
1244130

全球基因工程工具市场——行业规模、份额、趋势、机会、2018-2028 年预测、按类型、按治疗领域、按最终用户、按地区、按竞争

Genetic Engineering Tool Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2018-2028 Segmented By Type, By Therapeutic Area, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球基因工程工具市场预计在 2024-2028 年预测期内呈现强劲增长。

这可能是由于生物技术和遗传学领域的进步。 基因组医学和个性化医学的日益普及将推动未来几年全球基因工程工具市场的增长。 截至 2020 年，美国大约有 286 种个性化药物可用。

医药行业的增长带动市场增长

医疗保健行业正在全球范围内迅速扩张，增加对医疗保健行业发展的资金正在为市场增长创造更多有利可图的机会。 其中一个行业，即製药行业，是最先进的，由于在其生产、设计和製造中广泛使用基因工程工具，未来几年将实现巨大增长。 精准医学、基因组医学和其他先进疗法的快速增长将在未来五年进一步推动全球基因工程工具市场的增长。

基因工程在製药行业的第一个成功产品是胰岛素等蛋白质药物。 用作生物反应器的微生物被用来增加蛋白质的量和大量生产药物。 转基因动植物也被用来生产各种微生物不能生产的蛋白质药物。

研发和技术开发支持市场发展

基因工程是一个不断发展的生物技术领域。 由于对基因编辑和基因组操作的长期和持续研究，预计未来几年全球基因工程工具市场将出现强劲增长。 随着慢性病的流行和对这些疾病治疗方法的需求激增，全球基因工程工具市场将在预测期内出现增长。

微染色体技术或 RNA 转录修饰是主要的基因工程工具之一，有望得到进一步研究，从而支持未来几年全球基因工程工具市场的增长。 CRISPR-Cas9 基因改造是一种有望帮助市场增长的基因疗法。 此外，基因工程可以以多种方式应用。 基因工程工具在基因组修饰中的进一步应用是另一个有前途的研究领域，将在未来几年推动全球基因工程工具市场的增长。

农业基因工程

在基因工程的帮助下，对农业部门进步的需求进一步证明了未来几年全球基因工程工具市场的增长。 根据生物技术游说团体 ISAAA 的数据，2018 年，转基因作物种植面积为 1.917 亿公顷，比 2017 年增长 1%。 美国拥有 7500 万公顷土地（占世界的 39%），是世界上最大的转基因作物生产国。 提高作物产量，降低食品和药品生产成本，减少对杀虫剂的需求，强化营养素，提高食品质量，抵抗病虫害，增加粮食安全，增加全球人口医疗效果等是与使用相关的主要优势的基因工程工具。 基因工程工具参与农业生产更好的作物也将在未来几年推动全球基因工程工具市场的增长。

市场细分

全球基因工程工具市场根据类型、治疗领域、最终用户和地区进行细分。 根据类型，市场进一步细分为基因组规模的编辑工具和基因组规模的工程工具。 根据治疗领域，市场分为镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等。 基于最终用户，市场再次细分为生物技术和製药公司、学术研究机构等。 此外，市场分析将市场划分为亚太、北美、欧洲、南美、中东和非洲，并设计了区域市场细分。

公司简介

Thermo Fisher Scientific Inc、CRISPR Therapeutics AG、Editas Medicine, Inc、Intellia Therapeutics, Inc、Merck KGaA、Horizo□□n Discovery Ltd、GeneCopoeia Inc、Takara Bio Inc.、Sangamo Therapeutics, Inc、Genscript Biotech Corporation 等全球领先平台市场参与者引领基因工程工具市场的增长。

调查范围：

本报告将全球基因工程工具市场分为以下几类，行业趋势详述如下：

基因工程工具市场，按类型分类

  • 基因组规模的编辑工具
    • 基因编辑技术
    • 法师
    • 声明
    • 创建
    • 其他
  • 基因组规模的工程工具
    • 启动子工程
    • 核醣体结合位点 (RBS) 工程
    • 合成小分子调节 RNA
    • 其他
    • 基因工程工具市场，按治疗领域划分：
  • 镰状细胞病
  • 心脏病
  • 糖尿病
  • 阿尔茨海默氏痴呆症
  • 肥胖
  • 其他

最终用户的基因工程工具市场：

  • 生物技术公司、製药公司
  • 学术和研究机构等
  • 其他

按地区划分的基因工程工具市场

  • 北美
    • 美国
    • 墨西哥
    • 加拿大
  • 欧洲
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚
    • 泰国
    • 新加坡
  • 中东和非洲
    • 南非
    • 沙特阿拉伯
    • 阿联酋
    • 以色列
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚

竞争格局

公司概况：对全球遗传工具市场主要参与者的深入分析。

可自定义：

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势概述

第 4 章 VOC（客户之声）

  • 常用的基因工程技术
  • 常用的基因编辑技术
  • 基因重组工具的应用优势
  • 基因工程工具的优先级（按治疗领域）
  • 阻碍基因重组工具传播的事情
  • 品牌知名度

第五章基因工程工具的全球市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按类型（基因组规模编辑工具/基因组规模工程工具）
    • 按治疗领域（镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按公司分类（2022 年）
    • 按地区
  • 市场地图
    • 按类型
    • 按治疗领域
    • 最终用户
    • 按地区

第六章北美基因工程工具市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按类型（基因组规模编辑工具/基因组规模工程工具）
    • 按治疗领域（镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 墨西哥
    • 加拿大

第七章欧洲遗传工具市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按类型（基因组规模编辑工具/基因组规模工程工具）
    • 按治疗领域（镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第八章亚太基因工程工具市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按类型（基因组规模编辑工具/基因组规模工程工具）
    • 按治疗领域（镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳大利亚
    • 泰国
    • 新加坡

第9章南美遗传工具市场展望

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按类型（基因组规模编辑工具/基因组规模工程工具）
    • 按治疗领域（镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按国家
  • 南美洲：：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲基因工程工具的市场前景

  • 市场规模和预测
    • 按价值观
  • 市场份额和预测
    • 按类型（基因组规模编辑工具/基因组规模工程工具）
    • 按治疗领域（镰状细胞病、心脏病、糖尿病、阿尔茨海默病、肥胖症等）
    • 最终用户（生物技术/製药公司、学术/研究机构等）
    • 按国家
  • MEA：国家分析
    • 南非基因工程工具
    • 沙特阿拉伯基因工程工具
    • 阿联酋基因工程工具
    • 以色列基因工程工具

第 11 章市场动态

  • 司机
  • 做

第12章市场趋势与发展

  • 近期发展状况
  • 併购
  • 产品发布

第 13 章基因工程工具的全球市场：SWOT 分析

第 14 章波特的五力分析

  • 行业竞争
  • 新进入的可能性
  • 供应商的力量
  • 客户力量
  • 替代品的威胁

第15章竞争格局

  • Business Overview
  • Product Offerings
  • Recent Developments
  • Financials（As Reported）
  • Key Personnel
  • SWOT Analysis
    • Thermo Fisher Scientific Inc
    • CRISPR Therapeutics AG
    • Editas Medicine, Inc.
    • Intellia Therapeutics, Inc
    • Merck KGaA
    • Horizon Discovery Ltd
    • GeneCopoeia Inc
    • Takara Bio Inc
    • Sangamo Therapeutics, Inc.
    • Genscript Biotech Corporation

第16章 战略建议

简介目录
Product Code: 8085

Global genetic engineering tool market is expected to show robust growth in the forecast years 2024-2028. This can be ascribed to the increasing advancements in the field of biotechnology and genetics. The growing popularity of genomic medicine and personalized medicine is driving the growth of the global genetic engineering tool market in the coming years. As of 2020, the number of personalized medicine available in the United States was around 286.

The process of using recombinant Deoxyribonucleic Acid (rDNA) technology to create alterations in the genetic map of an organism is categorized as genetic engineering. These altercations are done through various biotechnological processes like insertion, deletion, CRISPR, etc. These techniques are termed genetic engineering tools. Genetic modifications have various purposes like pharmaceutical production, protein enhancement, genetic studies, etc., and thus genetic engineering tools are rapidly being introduced, and consistent research is being carried out.

Pharmaceutical Industry Growth Drives Market Growth

The Healthcare industry is rapidly expanding globally, and increasing financial aid for the development of the healthcare industry is further creating lucrative opportunities for the growth of market growth. One of the sectors, the pharmaceutical sector, is most advancing and registers phenomenal growth in the coming years due to the extended utilization of genetic engineering tools in their production, design, and manufacturing. The rapid growth of precision medicine, genomic medicine, and other advanced methods of therapeutics is further aiding the growth of the global genetic engineering tools market in the upcoming five years.

The first-ever successful product of genetic engineering in the pharmaceutical industry was protein drugs like insulin. Micro-organisms used as bioreactors were utilized to multiply the quantity of the protein and thus mass-produced the drug. Transgenic animals and transgenic plants are also utilized for the production of various protein drugs that are not possible to be produced in the micro-organisms.

Research & Technology Development Support Market Growth

Genetic engineering is a consistently developing sector of biotechnology. With prolonging and continuous research going on related to gene editing and genome manipulating studies, the global genetic engineering tool market is bound to register robust growth in the coming years. With the prevalence of chronic diseases and the surging demand for therapeutic approaches toward those diseases, the global genetic engineering tool market is supporting growth in the forecast period.

Minichromosomal technology and RNA transcription alterations are some of the major genetic engineering tools expecting more research, thereby supporting the growth of the global genetic engineering tools market in the coming years. CRISPR-Cas9 gene altercations is a gene therapy that is expected to aid market growth. Moreover, genetic engineering has various applications. Further applications of genetic engineering tools in genome modification are another prospective research segment that would drive the growth of the Global Genetic Engineering Tools market in the forecast years.

Genetic Engineering in Agriculture

Demands for advancement in the agriculture sector with the help of genetic engineering are further substantiating the growth of the global genetic engineering tool market in the coming years. According to the biotech lobbying group ISAAA, GM crops covered 191.7 million hectares in 2018, an increase of 1% from 2017. With 75 million hectares (39% of the world's area), the United States is the world's largest producer of GM crops. Increased crop yields, reduced costs for food or drug production, reduced need for pesticides, enhanced nutrient composition, and food quality, resistance to pests and disease, greater food security, and medical benefits to the world's growing population are some of the major advantages that involve the use of genetic engineering tools. The involvement of genetic engineering tools in agriculture to produce better crops will also drive the growth of the Global Genetic Engineering Tool market in the coming years.

Market Segmentation

Global genetic engineering tool market is segmented based on type, therapeutic area, end-user, and region. Based on type, the market is further fragmented into genome-scale editing tools and genome-scale engineering tools. Based on therapeutic areas, the market is bifurcated into sickle cell disease, heart disease, diabetes, Alzheimer's disease, obesity, and others. Based on end-user, the market is again sub-segmented into biotechnology & pharmaceutical companies, academic & research institutions, and others. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and the Middle East & African region.

Company Profiles

Thermo Fisher Scientific Inc, CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc, Merck KGaA, Horizon Discovery Ltd, GeneCopoeia Inc, Takara Bio Inc., Sangamo Therapeutics, Inc., Genscript Biotech Corporation, are among the major market players in the global platform that lead the market growth of the global genetic engineering tool market.

Report Scope:

In this report, global genetic engineering tool market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genetic Engineering Tool Market, By Type:

  • Genome-Scale Editing Tools
    • CRISPR
    • MAGE
    • CRMAGE
    • CREATE
    • Others
  • Genome-Scale Engineering Tools
    • Promoter Engineering
    • Ribosomal Binding Site (RBS) Engineering
    • Synthetic Small Regulatory RNA
    • Others
    • Genetic Engineering Tool Market, By Therapeutic Area:
  • Sickle Cell Disease
  • Heart Disease
  • Diabetes
  • Alzheimer's Disease
  • Obesity
  • Others

Genetic Engineering Tool Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutions
  • Others

Genetic Engineering Tool Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
    • Singapore
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Israel
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global genetic engineering tool market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Commonly Used Genetic Engineering Techniques
  • 4.2. Commonly Used Gene Editing Techniques
  • 4.3. Benefits of Using Genetic Engineering Tools
  • 4.4. Preference for Genetic Engineering Tools, By Therapeutic Area
  • 4.5. Barriers to Adoption of Genetic Engineering Tools
  • 4.6. Brand Awareness

5. Global Genetic Engineering Tools Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 5.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 5.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 5.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 5.2.4. By Company (2022)
    • 5.2.5. By Region
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Therapeutic Area
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Genetic Engineering Tools Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 6.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 6.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 6.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 6.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genetic Engineering Tools Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Therapeutic Area
        • 6.3.1.2.3. By End User
    • 6.3.2. Mexico Genetic Engineering Tools Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Therapeutic Area
        • 6.3.2.2.3. By End User
    • 6.3.3. Canada Genetic Engineering Tools Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Therapeutic Area
        • 6.3.3.2.3. By End User

7. Europe Genetic Engineering Tools Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 7.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 7.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 7.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 7.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Genetic Engineering Tools Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Therapeutic Area
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Genetic Engineering Tools Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Therapeutic Area
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Genetic Engineering Tools Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Therapeutic Area
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Genetic Engineering Tools Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Therapeutic Area
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Genetic Engineering Tools Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Therapeutic Area
        • 7.3.5.2.3. By End User

8. Asia-Pacific Genetic Engineering Tools Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 8.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 8.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 8.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 8.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Genetic Engineering Tools Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Therapeutic Area
        • 8.3.1.2.3. By End User
    • 8.3.2. India Genetic Engineering Tools Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Therapeutic Area
        • 8.3.2.2.3. By End User
    • 8.3.3. South Korea Genetic Engineering Tools Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Therapeutic Area
        • 8.3.3.2.3. By End User
    • 8.3.4. Japan Genetic Engineering Tools Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Therapeutic Area
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Genetic Engineering Tools Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Therapeutic Area
        • 8.3.5.2.3. By End User
    • 8.3.6. Thailand Genetic Engineering Tools Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Type
        • 8.3.6.2.2. By Therapeutic Area
        • 8.3.6.2.3. By End User
    • 8.3.7. Singapore Genetic Engineering Tools Market Outlook
      • 8.3.7.1. Market Size & Forecast
        • 8.3.7.1.1. By Value
      • 8.3.7.2. Market Share & Forecast
        • 8.3.7.2.1. By Type
        • 8.3.7.2.2. By Therapeutic Area
        • 8.3.7.2.3. By End User

9. South America Genetic Engineering Tools Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 9.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 9.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 9.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 9.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Genetic Engineering Tools Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Therapeutic Area
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Genetic Engineering Tools Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Therapeutic Area
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Genetic Engineering Tools Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Therapeutic Area
        • 9.3.3.2.3. By End User

10. Middle East and Africa Genetic Engineering Tools Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Genome Scale Editing Tools v/s Genome Scale Engineering Tools)
      • 10.2.1.1. Genome Scale Editing Tools (CRISPR, MAGE, CRMAGE, CREATE, Others)
      • 10.2.1.2. Genome Scale Engineering Tools (Promoter Engineering, Ribosomal Binding Site (RBS) Engineering, Synthetic Small Regulatory RNA, Others)
    • 10.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
    • 10.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Genetic Engineering Tools Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Therapeutic Area
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Genetic Engineering Tools Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Therapeutic Area
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Genetic Engineering Tools Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Therapeutic Area
        • 10.3.3.2.3. By End User
    • 10.3.4. Israel Genetic Engineering Tools Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Therapeutic Area
        • 10.3.4.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Genetic Engineering Tool Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1. Thermo Fisher Scientific Inc
    • 15.6.2. CRISPR Therapeutics AG
    • 15.6.3. Editas Medicine, Inc.
    • 15.6.4. Intellia Therapeutics, Inc
    • 15.6.5. Merck KGaA
    • 15.6.6. Horizon Discovery Ltd
    • 15.6.7. GeneCopoeia Inc
    • 15.6.8. Takara Bio Inc
    • 15.6.9. Sangamo Therapeutics, Inc.
    • 15.6.10. Genscript Biotech Corporation

16. Strategic Recommendations